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ABSTRACT 
Objective: This study aimed to compare between periostin and osteocalcin as biomarkers in Egyptian postmenopausal women with osteoporosis 
and to explore their possible relationship with fracture risk.  
Methods: This study included 90 postmenopausal females recruited from Al-Hussein University Hospital, Cairo, Egypt; divided into three groups; 
35 postmenopausal osteoporotic females with low fracture risk (group I), 35 postmenopausal osteoporotic females with high fracture risk (group 
II), and 20 apparently healthy controls. Serum periostin, osteocalcin, and estrogen were measured by Enzyme Linked Immunosorbent Assay 
(ELISA). Fracture risk assessment was calculated. Alkaline phosphatase (ALP), total and ionized calcium, Aspartate transaminase (AST), and Alanine 
transaminase (ALT) were measured spectrophotometrically. 
Results: The diagnostic performance of periostin for discriminating high fracture risk from low fracture risk groups showed the specificity of (68.6 %) 
and sensitivity of (100 %), while for osteocalcin the specificity was (51.4 %) and the sensitivity was (68.6 %) respectively. Moreover, the multi Receiver 
Operating Characteristics (multi-ROC) curve for periostin and osteocalcin together revealed improved specificity and sensitivity of (100 %) each.  
Conclusion: Periostin was superior to osteocalcin in discriminating high fracture risk from low fracture risk postmenopausal osteoporotic groups. 
Moreover, dual use of both markers gave the highest discriminative power between low and high fracture risk groups with 100 % specificity and sensitivity. 
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INTRODUCTION 
Osteoporosis is a skeletal metabolic disorder characterized by 
micro-architectural deterioration of bone tissue, this leads to an 
increase in bone fragility and fracture risk [1]. It is the most common 
metabolic bone disorder worldwide [2]. It was estimated that nearly 
1 in each 2 postmenopausal females above the age of 50 will suffer a 
fragility fracture at some point in their life-time [3]. 
Bone strength is a measure of the resistance to bone fracture, which 
is determined by a collection of many skeletal characteristics 
including: composition, microarchitecture, size, and shape [4]. Dual-
energy X-ray absorptiometry has been used widely for BMD 
measurement, bone strength assessment, and diagnosis of 
osteoporosis [5]. However, there are some limitations of DXA 
important to be considered. Bone mineral density (BMD) can be 
affected by positioning errors or artifacts, including osteoarthritis, 
fractures, and jewelry [6]. There are also many other factors that 
could affect DXA results, including recently administered 
gastrointestinal contrast or radionuclides, implants, devices, or any 
foreign material in the measurement area, and pregnancy [7]. 
Moreover, alkaline phosphatase (ALP) that has been usually used as 
a biomarker for osteoporosis, isn’t specific for bone, and originates 
from different organs as liver and kidney [8]. 
Bone turnover biomarkers usually result from the bone remodeling 
process and can be measured in urine or serum [9]. They are 
released throughout life to repair microfractures in bone and to 
maintain mineral homeostasis [10]. They are classified as markers of 
bone formation as total alkaline phosphatase, bone-specific alkaline 
phosphatase, osteocalcin, and procollagen type 1 N-terminal 
propeptide; and markers of bone resorption as hydroxyproline, 
deoxypyridinoline and pyridinoline [11]. 
Osteocalcin (OC) is a small protein (consists of 49 amino acids) 
encoded by the BGLAP gene synthesized by osteoblasts. The serum 
concentration of total OC has been considered a biochemical marker of 
osteogenesis that reflects the number and activity of osteoblasts [12]. 
It is the major and most thoroughly characterized bone-specific non 
collagenous protein in bone extracellular matrix that has been 
conserved in bone through evolution. It has a high affinity for calcium 
and plays an important role in matrix mineralization [13, 14]. 
Periostin, also named osteoblast-specific factor (OSF-2), is encoded 
by POSTN gene. It is an extracellular matrix protein of 836 amino 
acids with a molecular weight of approximately 93 kDa [15]. 
Periostin exists in the basement membrane and lung’s mesenchymal 
tissues. Its isomers are found also in the myocardium, skeletal 
muscle, heart valves, tendons, skin, periodontal ligaments, bones, 
and neoplastic tissues [16]. It is expressed predominantly in 
the periosteum , which covers the majority of bones and plays a vital 
role in regulating bone metabolism [17]. 
Periostin deficiency was related to osteoporosis and reduced bone 
strength [18]. The relationship between serum periostin, osteoporosis, 
and fracture risk in postmenopausal females is still unclear. Hence, the 
present work studies the possible relationship between serum 
periostin, BMD, estrogen, and fracture risk in Egyptian 
postmenopausal females compared to healthy postmenopausal 
controls. Moreover, the present study compares between periostin 
and osteocalcin performance as osteoporosis markers. 
MATERIALS AND METHODS 
Study population 
This study was conducted on 90 postmenopausal females with age 
range (50–62) years old), divided into 70 osteoporotic females 
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recruited from Rheumatology and Rehabilitation Department, Al-
Hussein University Hospital, Cairo, Egypt in the period from December 
2016 till March 2018, and 20 healthy postmenopausal volunteers taken 
as control group. Osteoporotic women were categorized into two 
groups; 35 with low fracture risk (group I) and 35 with high fracture risk 
(group II) according to the American Association of Clinical 
Endocrinologists (AACE) recommendations [19]. The present study 
conforms to recognized standards including Declaration of Helsinki, US 
Federal Policy for the Protection of Human Subjects, and European 
Medicines Agency Guidelines for Good Clinical Practice; and was 
approved by Research Ethical Committee of Faculty of Pharmacy, girls, 
Al-Azhar University (REC number: 252). Written consents were taken 
from every participant prior to their enrollment in the study. Also, all 
participants have given written informed consent for publication.  
Inclusion criteria 
1) Inclusion criteria for high fracture risk patients:  
a) Postmenopausal females with BMD T-score of–2.5 or below at 
spine and hip. 
b) Postmenopausal females with BMD T-score-1 to-2.5 at hip or 
spine with FRAX® 10-year probability for major osteoporotic 
fracture ≥ 20 % or the 10-year probability of hip fracture ≥ 3 %.  
2) Inclusion criteria for low fracture risk patients:  
Postmenopausal females with BMD T-score-1 to-2.5 at hip or spine 
with FRAX® 10-year probability for major osteoporotic fracture<20 
% or hip fracture<3 % [19, 20].  
3) Inclusion criteria for control group 
Postmenopausal females with BMD T-score of more than-1. 
Exclusion criteria 
1. Premenopausal and postmenopausal females with age more than 
62 y. 
2. Chronic diseases (Renal, Liver, Pulmonary, Cardiovascular, or any 
other major illness that could affect parameters. 
3. Patient taking medications for osteoporosis. 
4. Women who previously undergone a hysterectomy in young age. 
All participants were subjected to physical examination, full clinical 
examination with particular attention if there were low back pain, pain 
in spine, forearm or femur, and DXA scan to assess BMD. Assessment of 
serum calcium levels (total and ionized) and alkaline phosphatase were 
done by colorimetric methods. Liver function tests, including ALT and 
AST were done by the kinetic ultraviolet method using (Biolis50i 
Superior, Japan) to ensure that any rise in ALP levels originate from 
bone. Osteocalcin and periostin were estimated by ELISA (Tecan A-5082, 
Austria). Estrogen was assessed by ELISA (Biotek, Japan).  
Samples collection 
Blood samples (8 ml) were collected by trained laboratory 
technicians under complete aseptic conditions and allowed to clot 
for 30 min then centrifuged at 3000 rpm for 15 min. The serum was 
aspirated and divided into three aliquots, kept at-80 °c until an 
assessment of calcium (Ca), alkaline phosphatase (ALP), alanine 
transaminase (ALT), aspartate transaminase (AST), estrogen (E2), 
osteocalcin (OC), and periostin. 
Statistical analysis  
The Statistical Package for the Social Sciences (SPSS) (V. 24.0, IBM 
Corp., USA, 2016) was used for data analysis. Date was expressed as 
Median and Percentiles for quantitative nonparametric measures.  
The following tests were used; Wilcoxon Rank Sum was used for 
comparison between two independent groups, Kruskall Wallis was 
used for comparison between more than 2 patient groups, and 
Ranked Spearman correlation was used to study the possible 
association between two variables. The probability of error at 0.05 
or less was considered significant, while at 0.01 and 0.001 was 
considered highly significant. 
The Receiver Operating Characteristics (ROC) curves were 
constructed to obtain the most sensitive and specific cutoff values 
for each marker. Area under the curve (AUC) was calculated. 
RESULTS 
The Demographic data, clinical characters, and biochemical 
parameters of the control group, osteoporotic patients with low 
fracture risk (group I) and with high fracture risk (group II) were 
presented in table 1. Weight, body mass index and ALT were 
significantly increased in group I and group II compared to control 
group at **p ≤ 0.001 and **p ≤ 0.01, respectively. Total calcium and 
ionized calcium showed a significant decrease in group I and group II 
compared to control group (**p ≤ 0.001), while osteocalcin, ALP, and 
periostin showed a significant increase in group I and group II 
compared to control group (**p ≤ 0.001). Moreover, spine BMD T-
score and total hip BMD T-score showed a significant decrease, while 
major osteoporotic (FRAX) (%) and hip fracture (FRAX) (%) showed 
significant increase in group I and group II compared to the control 
group (**p ≤ 0.001), as mentioned previously in inclusion criteria. 
 
Table 1: Demographic, clinical, and biochemical parameters of all studied groups 
Variables Control (n = 20) Group I (n = 35) Group II (n = 35) p value 
Age (Years) (25Perc-75perc) 57.5 (50.25-60.75) 58.1 (53-59) 60 (57-62) 0.213 
Height (Cm) (25Perc-75perc) 156 (153-158.75) 155 (151-159) 157 (149-160) 0.906 
Weight (Kg) (25Perc-75perc) 64 (60-72.25) 77a (69-85) 80a (70-97) 0.001** 
BMI (Kg/m2) (25Perc-75perc) 26.85 (24.55-30.55) 32.4a (29.1-37.3) 35a (27.3-39.3) 0.001** 
ALT (U/l) (25Perc-75perc) 6 (4-7) 7 (4-12) 11a (6-14)  0.016** 
AST (U/l) (25Perc-75perc) 6.5 (4.25-9) 9 (6-13) 9 (5-14) 0. 135 
Total Ca (mg/dl) (25Perc-75perc) 9.79 (9.6-10.2175) 6.04a (5.4-7.03) 5.48a,b (5.06-6.23) 0** 
Ionized Ca (mg/dl) (25Perc-75perc) 4.62 (4.5925-4.6875) 4.59 (4.18-4.9) 4.18a,b (3.95-4.58) 0** 
ALP (U/l) (25Perc-75perc) 108 (98.25-116.25) 350a (315-369) 454a,b (409-472) 0** 
Spine BMD T-score (25Perc-75perc) -0.1 (-0.3-0.675) -2a (-2.8-(-1.1)) -2.2a (-2.7-(-0.3)) 0** 
 Total hip BMD T-score (25Perc-75perc) 0.45 (0-1.075) -1.7a (-2-(-1.4)) -2.3a,b (-2.4-(-1.4)) 0** 
Major osteoporotic (FRAX) (%) (25Perc-75perc) 2.2 (1.6-2.75) 6.3a (4.2-8.7) 15a,b (11.9-18) 0** 
Hip fracture (FRAX) (%) (25Perc-75perc) 0.1 (0-0.1) 1.1a (0.9-1.9) 5a,b (3.9-6.4) 0** 
Estrogen (pg/ml) (25Perc-75perc) 5.5 (3.25-8) 5 (3-10) 6 (3-11) 0.434 
Osteocalcin (ng/ml) (25Perc-75perc) 7.15 (5.4-11.125) 26.2a (23.9-29) 27.7a (25.5-30) 0** 
Periostin (ng/ml) (25Perc-75perc) 483 (411.75-564.75) 817.5a (710-886) 1102a,b (915-1340) 0** 
a: Significant difference from control group, b: Significant difference from group I, *p ≤ 0.05 was considered significant, **p ≤ 0.01 and 0.001 were 
considered highly significant.  
 
Correlation of osteocalcin with the other studied parameters revealed 
positive significant correlation with ALP in group I and group II (r = 
0.898, **p ≤ 0.001) and (r = 0.938, **p ≤ 0.001) respectively. There were 
also positive significant correlations between osteocalcin and each of 
major osteoporotic (FRAX) (%) and hip fracture (FRAX) (%) in group II 
(r = 0.791, **p ≤ 0.001) and (r = 0.922, **p ≤ 0.001) respectively (table 2). 
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Table 2: Correlation of osteocalcin (ng/ml) with all studied parameters in controls, group I, and group II 
Studied parameters Correlation of osteocalcin (ng/ml) 
Control (n = 20) Group I (n = 35) Group II (n = 35) 
r-value p value  r-value p value  r-value p value  
Total Ca (mg/dl) 0.212 0.369 -0.128  0.465 -0.054 0.757 
Ionized Ca (mg/dl) 0.132 0.579 -0.135 0.438 -0.235 0.175 
ALP (U/l) 0.108 0.651 0.898 0** 0.979 0** 
Spine BMD T-score -0.289 0.216 -0.092 0.6 -0.266 0.192 
Total hip BMD T-score -0.443 0.051 -0.07 0.69 -0.249 0.15 
Major osteoporotic (FRAX) (%) 0.681  0.001** 0.09 0.607 0.791 0** 
Hip fracture (FRAX) (%) 0.601 0.005* 0.113 0.518 0.922 0** 
Estrogen (pg/ml) -0.45 0.046* -0.342 0.045* -0.066 0.706 
*p ≤ 0.05 was considered significant, **p ≤ 0.01 and 0.001 were considered highly significant. 
 
The correlation between periostin and the other studied parameters 
revealed positive significant correlation between periostin and ALP 
in group I and group II (r-value = 0.952, **p ≤ 0.001) and (r-value = 
0.992, **p ≤ 0.001) respectively. There were also positive significant 
correlations between periostin and each of major osteoporotic 
(FRAX) (%) and hip fracture (FRAX) (%) in group II (r-value = 0.754, 
**p ≤ 0.001) and (r-value = 0.886, **p ≤ 0.001) respectively and 
negative significant correlation with estrogen in controls and group I 
(r-value =-0.648, **p ≤ 0.01) and (r-value =-0.356, **p ≤ 0.05) 
respectively. Moreover, periostin showed positive significant 
correlation with osteocalcin in groups I and II (r-value = 0.938, **p ≤ 
0.001) and (r-value = 0.958, **p ≤ 0.001) respectively (table 3). 
 
Table 3: Correlation of periostin (ng/ml) with all studied parameters in controls, group I, and group II 
 Studied parameters Correlation of periostin (ng/ml) 
Control (n = 20) Group I (n = 35) Group II (n = 35) 
r-value p value  r-value p value  r-value p value  
Total Ca (mg/dl) -0.239 0.311 -0.173 0.32 -0.141 0.419 
Ionized Ca (mg/dl) -0.071 0.768 -0.194  0.265 -0.076 0.663 
ALP (U/l) 0.02 0.935 0.952 0** 0.992 0** 
Spine BMD T-score -0.042 0.859 -0.04 0.82 -0.284 0.099 
Total hip BMD T-score 0.058 0.809 -0.003 0.986 -0.021 0.227 
Major osteoporotic (FRAX) (%) 0.406 0.075 0.05 0.774 0.754 0** 
Hip fracture (FRAX) (%) 0.433 0.057 0.074 0.672 0.886 0** 
Estrogen (pg/ml) -0.648 0.002** -0.356 0.036* -0.25 0.978 
Osteocalcin (ng/ml) 0.406 0.075 0.938 0** 0.958 0** 
*p ≤ 0.05 was considered significant, **p ≤ 0.01 and 0.001 were considered highly significant. 
 
Table (4) and (fig. 1) represents the output data of the receiver 
operating characteristics (ROC) curve for each of serum 
periostin and osteocalcin. At cut off 602 for periostin, the 
specificity and sensitivity were (68.6 % and 100 %) 
respectively. At cut off 20.7 for osteocalcin, the specificity and 
sensitivity were (51.4 % and 68.6 %) respectively. Multi-ROC 
curve showed a huge improvement in the discriminative power 
of periostin and osteocalcin when used together as the 
sensitivity and specificity raised to 100 %, at cut off value of 
850 for periostin. 
 
Table 4: The discriminative power of serum periostin (ng/ml), osteocalcin (ng/ml), and combined (periostin/osteocalcin) between group 
I and group II osteoporotic patients 
Variable Cutoff AUC % Sensitivity % Specificity % Efficacy 
Periostin (ng/ml)  850 1.000 100.0 68.6 84.3 
Osteocalcin (ng/ml) 26.2 0.995 68.6 51.4 60 
Multi-ROC: for periostin (ng/ml) at 850 
Osteocalcin (ng/ml) 32.5 1 100.0 100.0 100.0 
 
 
Fig. 1: ROC curve for discriminating patients with high fracture risk from those with low fracture risk showing the diagnostic performance 
of periostin (ng/ml), osteocalcin (ng/ml), and multi ROC for their combination 
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DISCUSSION 
Osteoporosis is usually caused by altered bone micro-structure 
predisposing patients to fragility and fractures [21]. Introducing a 
biomarker that could predict the risk of bone fracture would help in 
the early therapeutic intervention, reducing future fractures, and 
complications. 
In the current study, there were reductions in spine BMD T-score, 
total hip BMD T-score, and serum Ca in group I and group II 
compared to the control group (**p ≤ 0.001). This was matched with 
a study done by Tian et al. [22] who reported lower serum Ca and 
BMD in postmenopausal osteoporotic than non-osteoporotic 
females. Moreover, Qu et al. found lower BMD in the fracture group 
than in the non-fracture group; and in elder females than younger 
females. They stated that the risk of fracture increases with the 
reduction in bone density [23]. 
In the present study, major osteoporotic (FRAX) (%) and hip 
fracture (FRAX) (%) showed significant increases in group I and 
group II compared to control group. This result was similar to 
Tomasevic et al. who concluded that osteoporosis patients had a 
high risk of Major osteoporotic (FRAX) and hip fracture (FRAX) 
%. They indicated that patients suffering from osteoporosis and 
who had a history of fractures had higher fracture risk in 
comparison to those suffering from osteopenia without history 
of fractures [24]. 
In the present work, osteocalcin showed a significant increase in 
both patients’ groups compared to the control group at **p ≤ 0.001 
while no significant difference was obtained between groups I and II. 
This was matched with a study done by Alam et al. who reported a 
significant increase of osteocalcin in postmenopausal osteoporotic 
patients and explained it by accelerated osteoclastic activity due to 
the sudden depletion of estrogen which increases bone resorption 
on the expense of bone formation that is reflected in serum as 
increased osteocalcin levels [25]. 
Beg et al. reported that serum osteocalcin was significantly higher in 
postmenopausal females with osteoporosis than without (*p<0.05). 
They reported reduced osteocalcin levels after treatment with 
risedronate, an osteoporosis medication; and concluded that 
osteocalcin can be potentially useful in the diagnosis and the 
monitoring of response to therapy in osteoporotic patients [26].  
Singh et al. recommended the use of serum osteocalcin level as a 
screening tool for osteoporosis in postmenopausal females and 
advised only subjects having osteocalcin levels beyond osteocalcin 
cutoff point for DXA scan to grade the severity of osteoporosis [27]. 
Soroosh et al. discussed the relation between osteocalcin and bone 
formation by the following; Osteocalcin is produced by osteoblasts 
during bone formation process and binds to the c-carboxyglutamic 
acid (Gla) residues by its high affinity for calcium. This promotes the 
absorption of calcium to the hydroxyapatite in bone matrix and aids 
mineralization of bone. Decreases in bone mineralization (decreased 
hydroxyapatite crystal formation) in osteoporosis causes free 
osteocalcin to circulate in the blood and hence results in increased 
serum osteocalcin levels [28]. 
On the contrary, Rai et al. found very low levels of serum osteocalcin 
in postmenopausal females with fractures compared to the 
premenopausal females and linked it with reduced bone formation 
and increased resorption activity at late menopause [29]. 
Moreover, Liu et al. found no significant difference of the pooled 
serum osteocalcin in postmenopausal osteoporotic patients in 
comparison with postmenopausal controls. They recommended not 
to use serum osteocalcin as indicator for high bone turnover status 
in postmenopausal females unless new techniques for standardized 
circulatory osteocalcin evaluation are introduced in the future, since 
osteocalcin molecules are quite heterogeneous (different fragments 
and different carboxylation status) in the circulation, and can be 
influenced by many metabolic events [30].  
The previously discussed controversy demonstrates that osteocalcin 
could not be considered as a reliable marker for osteoporosis 
diagnosis and monitoring; hence it appears the necessity of 
searching for new biomarkers.  
Regarding the correlation of osteocalcin with other biomarkers, 
there were significant positive correlations with ALP in group I and 
group II. This was compatible with the results obtained by Singh et 
al. who stated that alkaline phosphatase had a strong positive 
correlation with serum osteocalcin level [27].  
In the present study, there were no significant correlations between 
osteocalcin and each of (total hip BMD T-score and spine BMD T-
score) in group I and group II. This was in accordance with a study 
done by Soroosh et al. who stated that serum osteocalcin levels did 
not correlate significantly with BMD in postmenopausal 
osteoporosis females [28].  
In the current study, there were significant positive correlations 
between osteocalcin and each of (major osteoporotic (FRAX) % and 
hip fracture (FRAX) %) in group II. This was matched with Dai et al. 
who found a dose-dependent positive relationship between 
osteocalcin and the risk of hip fracture in Asian population [31]. 
In the current study, periostin showed a significant increase in both 
patients’ groups compared to the control group at **p ≤ 0.001 and a 
significant increase in high fracture risk group than the low fracture risk 
group at **p ≤ 0.001. This means that high level of periostin was 
associated with an increased risk of fracture. These findings were agreed 
with a study done by Bonnet et al. who found periostin increased in 
females with incident fracture than those without [32]. Kim et al. and 
Sakellariou et al. found high serum periostin levels associated with 
increased fracture risk in postmenopausal females [33, 34].  
Varugheseet al. reported elevated serum periostin levels in response to 
bone injury and repair. They observed elevated periostin levels also in 
patients with radiological evidence of osteoporotic fracture [16].  
Circulating periostin may reflect the adaptation of the metabolic 
activity of periosteum cells to the existing bone strains for 
maintenance of a stabilized bone quality. Women with lower bone 
mass and strength may have a higher mechanical strain in the 
remaining bone that would increase periostin expression. Thus, 
increased expression of periostin is reflected in serum by an 
increase of circulating periostin. However, at the level of bone, an 
increase of bone formation caused by an increased periostin 
expression is not enough to compensate the bone loss leading to 
fragility fractures [35]. 
De Lageneste et al. explained the role of periostin in bone 
regeneration by the activation of skeletal stem cells (SSCs) in the 
periosteum causing a high bone regenerative potential, 
reconstituting a pool of periosteal cells after injury [36]. Zhang et al. 
explained that mechanical activity and exercise may increase 
periostin production in osteoblasts, which in turn may inhibit the 
differentiation of osteoclasts by its effects on semaphorin-3A [37].  
Kudo. explained that the cortical bone formation is regulated by the 
periostin-mediated blocking of random bone formation. They stated 
that, in response to mechanical stress, periostin expression is 
enhanced, and activates cellular functions to improve the irregular 
collagen fibrillogenesis and extracellular matrix organization to 
maintain tissue homeostasis [38]. 
Yan et al. found the initial levels of periostin after fracture 
significantly higher in osteoporotic patients than controls revealing 
that high periostin level was an independent predictor of femoral 
neck BMD in elderly females presenting with acute hip fracture. 
They declared that increased periostin levels during early healing 
phase may imply that periostin play a role in bone repair [39]. 
Luo and Deng. found no significant differences in serum periostin levels 
between postmenopausal females with normal and abnormal BMD T-
score, and reported that periostin is not a predictor of early-stage bone 
deterioration in Chinese postmenopausal females. However, during the 
course of their study, BMD data at one year after baseline indicated that 
the femur neck bone mineral content (BMC) and T-score became lower 
in women with higher baseline serum periostin [40]. This indicates a 
powerful relation of periostin and BMD.  
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In the present work, no significant correlations were obtained 
between periostin and bone mineral density in the three groups. 
This result is compatible with Walsh et al. who reported that there 
were no significant correlations between serum periostin and BMD 
at the lumbar spine or total hip, when analyzed as a group and 
within each group [41].  
However, Gossiel et al. revealed that the changes in periostin levels 
were positively correlated with the changes in total hip BMD and 
femoral neck BMD in postmenopausal females with osteoporosis 
after treatment with teriparatide [42]. 
In the present work, there was a significant positive correlation 
between periostin and each of (major osteoporotic (FRAX) (%) and 
hip fracture (FRAX) (%)) in group II. This was matched with Terpos 
et al. who stated that periostin was elevated in the bone marrow 
plasma and in the serum of newly diagnosed symptomatic multiple 
myeloma patients and correlates with extensive bone lytic lesions, 
bone fractures and extensive osteolysis [43].  
Also, there were no significant correlations between periostin and 
each of (total hip BMD T-score and spine BMD T-score) in both 
patients’ groups in the present study. This was as the findings of 
Rousseau et al. who reported that serum periostin was not 
significantly associated with BMD of the spine or the hip [44]. Yan et al. 
reported that serum periostin level was negatively correlated with 
femoral neck BMD, an acute hip fracture was associated with a 
transient change of serum periostin levels in older females, and that 
measurement of serum periostin around the time of bone healing 
phase may include assessment of response to fracture therapy [39]. 
In the current work, there was a significant positive correlation 
between periostin and ALP in group I and group II. This result is 
compatible with Anastasilakis et al. [45] and in contrast with Hu et 
al. [46]. 
In the current work, there was a significant positive correlation between 
osteocalcin and periostin in group I and group II. However, the 
diagnostic performance of periostin and osteocalcin in discrimination 
between group I and group II using ROC curves revealed a more 
powerful discriminating capability of periostin than osteocalcin. The best 
cutoff value of periostin was taken at 850 ng/ml with specificity and 
sensitivity (100 % and 68.6 %), respectively, while the best cutoff value 
of osteocalcin was taken at 26.2 ng/ml with specificity and sensitivity 
(68.6 % and 51.4 %) respectively. Moreover, a multi ROC curve was 
performed for periostin and osteocalcin together and revealed improved 
specificity and sensitivity of 100 % for each at the cut off values (850 and 
32.5), respectively.  
CONCLUSION 
The present study implies a potential role of periostin as a 
promising biomarker for the prediction of fracture risk in 
postmenopausal osteoporotic females. Moreover, periostin was 
superior to osteocalcin in discrimination of high fracture risk from 
low fracture risk patients. On top of that and according to the 
studied Egyptian population, Dual assessment of osteocalcin, and 
periostin seemed to be more efficient in identifying high fracture 
risk from low fracture risk osteoporosis patients than the use of 
each of them alone. 
LIMITATIONS AND RECOMMENDATIONS 
• The number of participants in the present study was the 
maximum number that authors could afford financially as this study 
was completely self-funded, so further studies are recommended on 
large scale to confirm our results. 
• The present study involved only postmenopausal women so 
further studies are recommended to examine the role of periostin as 
a biomarker for senile osteoporosis in both sex groups and in 
different age groups.  
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